NCT01846390 - Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2013

Primary Completion Date

July 6, 2016

Study Completion Date

September 19, 2018

Conditions

Peripheral T-Cell LymphomaDiffuse Large B-Cell Lymphoma

Interventions

DRUG

Gemcitabine

Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.

DRUG

Dexamethasone

40 mg D1 - D4

DRUG

Cisplatin

75 mg/m2 D1

DRUG

Romidepsin

Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.

Trial Locations (6)

Tom Baker Cancer Centre, Calgary

BCCA - Vancouver Cancer Centre, Vancouver

Regional Health Authority B, Zone 2, Saint John

QEII Health Sciences Centre, Halifax

Odette Cancer Centre, Toronto

Univ. Health Network-Princess Margaret Hospital, Toronto